Core Insights - Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies aimed at restoring vision and preventing blindness in patients with inherited retinal diseases (IRDs) [4] Company Overview - The company is developing durable, one-time treatments that target the underlying genetic causes of severe retinal disorders [4] - Opus Genetics has a pipeline that includes seven AAV-based programs, with key candidates being OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration [4] - Additional candidates in development target RHO, RDH12, and MERTK [4] - The company is also advancing Phentolamine Ophthalmic Solution 0.75%, which is approved for pharmacologically induced mydriasis, with further indications in late-stage development for presbyopia and low-light visual disturbances following keratorefractive surgery [4] - Opus Genetics is headquartered in Research Triangle Park, NC [4] Upcoming Events - Management will participate in the BTIG 5th Annual Ophthalmology Day on December 1, 2025, with Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, in a fireside chat at 1:00 p.m. ET [2] - George Magrath, M.D., Chief Executive Officer, will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:00 a.m. ET in New York, NY [2] - A link to the live and archived webcast for the Piper Sandler conference will be available on the company's website under the Investors section [3]
Opus Genetics to Participate in Upcoming Investment Conferences